What does the evidence say about Bergamot Cardiometabolic Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Bergamot Cardiometabolic Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Bergamot ( Citrus bergamia ), a flavonoid-rich nutraceutical, has shown potential cardiometabolic benefits, yet evidence from human trials remains inconsistent. [Chambari M (2026); evidence level 1] - This systematic review and dose-response meta-analysis evaluated the effects of bergamot ( Citrus bergamia ) on cardiovascular disease risk factors in adults. [Chambari M (2026); evidence level 1] - The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. [Chambari M (2026); evidence level 1] - Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western countries, characterized by excessive fat storage in the form of lipid droplets (LDs) in hepatocytes; it is also called Metabolic-Associated Steatotic Liver Disease (MASLD), if coexisting with at least one cardiometabolic risk factor. [Riillo C (2025); evidence level 4] - Bergamot polyphenols (BPF) have been shown to counteract hepatic LD accumulation through potent lipogenesis suppression and associated metabolic benefits in Wistar rats, but their liver-specific anti-lipogenic effects may be species- and strain-dependent. [Riillo C (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.